R. Guest

发表

P53 integrity in the genetically engineered mammalian cell lines AHH-1 and MCL-5.

J. Parry, R. Guest, 1999, Mutation research.

The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity

S. Halford, K. Chester, R. Guest, 2017, Cancer Immunology, Immunotherapy.

The Role of Extracellular Spacer Regions in the Optimal Design of Chimeric Immune Receptors: Evaluation of Four Different scFvs and Antigens

P. Stern, K. Chester, R. Guest, 2005, Journal of immunotherapy.

Primary Polyclonal Human T Lymphocytes Targeted to Carcino-Embryonic Antigens and Neural Cell Adhesion Molecule Tumor Antigens by CD3ζ-Based Chimeric Immune Receptors

R. Guest, M. Lehane, D. Gilham, 2002, Journal of immunotherapy.

Gene Therapy of Patient-Derived T Lymphocytes to Target and Eradicate Colorectal Hepatic Metastases

R. Guest, J. Irlam, D. Gilham, 2003, Diseases of the colon and rectum.

T-Cell Engineering and Expansion — GMP Issues

Cor Lamers, Ryan D. Guest, R. Guest, 2014 .

Immunotherapy Bridge 2021 and Melanoma Bridge 2021: meeting abstracts

R. Sullivan, R. Dummer, J. Kirkwood, 2022, Journal of Translational Medicine.

Definition and application of good manufacturing process-compliant production of CEA-specific chimeric antigen receptor expressing T-cells for phase I/II clinical trial

R. Guest, F. Thistlethwaite, D. Gilham, 2014, Cancer Immunology, Immunotherapy.

First generation anti-CD19 chimeric antigen receptor-modified T cells for management of B cell malignances: initial analysis of an ongoing Phase I clinical trial

R. Guest, F. Thistlethwaite, D. Gilham, 2014, Journal of Immunotherapy for Cancer.

Evidence of clinical efficacy of a first generation CD19 CAR T cell in B cell malignancies

R. Guest, F. Thistlethwaite, D. Gilham, 2023, eJHaem.